Response to Comparison of Teriparatide and Strontium Ranelate in Postmenopausal Women with Osteoporosis
Abstract
The statistically significant reductions compared to baseline in serum PINP and β-CTx in the SrR group indicate a weak inhibition of bone turnover activity at the dose used in humans and should be taken into account when analyzing the different effects of these two drugs on the bone remodeling cycle using bone biopsies. Changes in microarchitecture induced by SrR in human biopsies cannot be considered as proof of the anabolic effects of this drug, at least at the doses used in humans.
These analyses were cross-sectional and not based on paired biopsies. The microstructural differences seen from µCT of iliac bone biopsies from SrR and placebo treated women were very similar to those described with classical antiresorptives such as alendronate and zoledronate in similar cross-sectional analyses.